This Quantum Computing Company's Backlog Just Increased Nearly 2,000%

D-Wave reported Q1 2026 bookings of $33.4 million, up 1,994% year over year, driven by a $20 million purchase from Florida Atlantic University and a separate $10 million Fortune 100 agreement. The article argues that D-Wave's quantum annealing systems are already usable in real-world optimization tasks, supporting the investment case for the stock and the broader quantum computing sector. The tone is constructive but still cautious given execution and industry risk.

Analysis

QBTS is not being re-rated because quantum is "here" in the abstract; the important shift is that one narrow, monetizable use case is beginning to look procurement-worthy. That matters because enterprise tech budgets almost never fund frontier R&D for its own sake—they fund painkillers with measurable payback. If D-Wave can keep converting pilot interest into capex-like purchases, the market will start underwriting a recurring systems + services model rather than a science-project multiple.

The second-order winner is not just QBTS, but adjacent vendors that can sell a "quantum readiness" stack: consulting, optimization software, hybrid cloud orchestration, and cryogenic/component suppliers. The real competitive threat is to legacy optimization workflows and generic OR software vendors, not to GPUs or classical compute broadly. In fact, the more quantum annealing proves useful in scheduling and logistics, the more it becomes a wedge product for deeper enterprise lock-in before gate-based machines are commercially relevant.

Consensus is probably overestimating how quickly this becomes a platform market and underestimating how valuable a few lighthouse customers can be for sentiment. The base case remains lumpy bookings, long evaluation cycles, and headline-driven volatility; one or two deals can move the stock far more than fundamentals justify. The key risk is not technical obsolescence in the next quarter, but a slowdown in conversion if early adopters fail to prove repeatable ROI inside 6-12 months.

For now, the stock is a high-beta sentiment proxy on "quantum as product," so the trade is more about timing and positioning than valuation. If more enterprise orders follow within the next 1-2 quarters, the multiple can expand quickly off a very small revenue base. If not, the tape will likely punish it as a story stock with no durable operating leverage.

Key Decisions for Investors

• Long QBTS as a tactical momentum trade over the next 1-3 months; size small because the setup is asymmetric to headlines, but exit quickly if follow-on bookings do not appear in the next two quarters.
• Buy QBTS call spreads 3-6 months out to express upside convexity with defined downside; best if you expect one or two additional enterprise wins rather than a broad fundamentals re-rating.
• Pair long QBTS / short a basket of mature optimization or workflow software names if you want to isolate the "quantum readiness" adoption theme; this works only if procurement interest starts to cannibalize legacy spend.
• Avoid chasing after big gap-ups; use post-rally pullbacks as entry points because sentiment can overshoot on each contract announcement and retrace hard when no new catalyst follows.
• For longer-duration capital, prefer a basket/ETF approach over single-name risk; the probability-weighted outcome for QBTS remains high dispersion over 12-24 months.